Key Insights

Highlights

No notable highlights available yet

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

0.0%

0 terminated out of 7 trials

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

7Total
Not Applicable (2)
Early P 1 (1)
P 1 (1)
P 2 (2)
P 4 (1)

Trial Status

Recruiting3
Not Yet Recruiting3
Active Not Recruiting1

Clinical Trials (7)

Showing 7 of 7 trials
NCT07583641Phase 2Not Yet RecruitingPrimary

A Study to Learn About How Well the Medicine Efgartigimod Works to Treat Autoimmune Encephalitis In Children 12 Years or Older and Adults

NCT07707739Not ApplicableNot Yet RecruitingPrimary

Plasma Exchange in Pediatric Autoimmune Encephalitis

NCT07689682Not ApplicableActive Not RecruitingPrimary

OPM- MEG in Non-immune And iMmune-medIated Neurological Disease

NCT07686042Phase 4Not Yet RecruitingPrimary

Efficacy and Safety of Low-Dose Blinatumomab in the Treatment of Refractory Autoimmune Encephalitis and Autoimmune Cerebellitis

NCT07337785Early Phase 1Recruiting

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

NCT07526493Phase 1Recruiting

Safety and Pharmacodynamics of QH103 Cell Injection in the Treatment of Patients With Relapsed/Refractory Antibody-Mediated Neurological Autoimmune Diseases.

NCT07488117Phase 2RecruitingPrimary

Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?

Showing all 7 trials

Research Network

Activity Timeline